Skip to main content

Vyvanse Side Effects

Generic name: lisdexamfetamine

Medically reviewed by Philip Thornton, DipPharm. Last updated on Feb 1, 2024.

Note: This document contains side effect information about lisdexamfetamine. Some dosage forms listed on this page may not apply to the brand name Vyvanse.

Applies to lisdexamfetamine: oral capsule, oral tablet chewable.

Warning

Oral route (Capsule)

Abuse, Misuse, and AddictionLisdexamfetamine dimesylate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.Before prescribing lisdexamfetamine dimesylate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout lisdexamfetamine dimesylate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Serious side effects of Vyvanse

Along with its needed effects, lisdexamfetamine (the active ingredient contained in Vyvanse) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lisdexamfetamine:

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking lisdexamfetamine:

Symptoms of overdose

Other side effects of Vyvanse

Some side effects of lisdexamfetamine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to lisdexamfetamine: oral capsule, oral tablet chewable.

Other

Common (1% to 10%): Pyrexia, increased energy, fatigue[Ref]

Gastrointestinal

Very common (10% or more): Dry mouth (36%), upper abdominal pain (12%)

Common (1% to 10%): Vomiting, nausea, diarrhea, constipation, gastroenteritis[Ref]

Metabolic

Very common (10% or more): Decreased appetite (39%), decreased weight (16.3%)

Common (1% to 10%): Anorexia[Ref]

Nervous system

Very common (10% or more): Headache (20.3%)

Common (1% to 10%): Dizziness, somnolence, tremor, paresthesia, nightmare, dyskinesia, seizures, psychomotor hyperactivity

Postmarketing reports: Dyskinesia[Ref]

Psychiatric

Very common (10% or more): Insomnia (27%), irritability (10%)

Common (1% to 10%): Tic, anxiety, agitation, erectile dysfunction, decreased libido, affect lability, feeling jittery, restlessness, aggression, initial insomnia, bruxism

Uncommon (0.1% to 1%): Logorrhea, depression, dysphoria, euphoria, dermatillomania, mania, hallucinations

Postmarketing reports: Libido changes, frequent or prolonged erections, psychotic episodes[Ref]

Dermatologic

Common (1% to 10%): Rash, hyperhidrosis, pruritus

Uncommon (0.1% to 1%): Urticaria

Postmarketing reports: Stevens-Johnson Syndrome, angioedema[Ref]

Cardiovascular

Common (1% to 10%): Increased blood pressure, increased heart rate, tachycardia, palpitations

Uncommon (0.1% to 1%): Raynaud's phenomenon

Postmarketing reports: Cardiomyopathy[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity

Postmarketing reports: Anaphylactic reaction[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Ocular

Uncommon (0.1% to 1%): Mydriasis, blurred vision

Postmarketing reports: Diplopia, visual accommodation difficulties[Ref]

Hepatic

Postmarketing reports: Eosinophilic hepatitis[Ref]

Musculoskeletal

Postmarketing reports: Rhabdomyolysis[Ref]

Respiratory

Common (1% to 10%): Dyspnea, oropharyngeal pain[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Vyvanse (lisdexamfetamine). Shire US Inc. 2007.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.